Massachusetts Financial Services CO Prothena Corp Public LTD CO Transaction History

Massachusetts Financial Services CO

$282 Billion
Q1 2025

A detailed history of Massachusetts Financial Services CO transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Massachusetts Financial Services CO holds 43,816 shares of PRTA stock, worth $354,033. This represents 0.0% of its overall portfolio holdings.

Number of Shares

43,816

Previous 44,815 2.23%

Holding current value

$354,033

Previous $620,000 12.58%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 02, 2025	SELL	$12.38 - $16.04 $12,367 - $16,023	-999 Reduced 2.23%	43,816 $542,000
Q4 2024 Feb 12, 2025	BUY	$11.95 - $18.35 $535,539 - $822,355	44,815 New	44,815 $620,000
Q2 2022 Aug 09, 2022	SELL	$22.73 - $39.98 $308,127 - $541,968	-13,556 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$30.27 - $49.22 $856,701 - $1.39 Million	-28,302 Reduced 67.61%	13,556 $496,000
Q4 2021 Feb 10, 2022	SELL	$42.11 - $73.26 $35,709 - $62,124	-848 Reduced 1.99%	41,858 $2.07 Million
Q3 2021 Nov 10, 2021	SELL	$48.2 - $78.89 $27,088 - $44,336	-562 Reduced 1.3%	42,706 $3.04 Million
Q2 2021 Aug 13, 2021	SELL	$21.63 - $57.65 $650,435 - $1.73 Million	-30,071 Reduced 41.0%	43,268 $2.22 Million
Q1 2021 May 13, 2021	SELL	$11.0 - $28.24 $387,805 - $995,601	-35,255 Reduced 32.46%	73,339 $1.84 Million
Q4 2020 Feb 12, 2021	BUY	$10.12 - $13.94 $216,294 - $297,939	21,373 Added 24.5%	108,594 $1.3 Million
Q3 2020 Nov 12, 2020	BUY	$9.93 - $13.47 $866,104 - $1.17 Million	87,221 New	87,221 $871,000

Others Institutions Holding PRTA

# of Institutions

195

Shares Held

39.4M

Call Options Held

601K

Put Options Held

259K

View Full List

About PROTHENA CORP PUBLIC LTD CO

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $379M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

More about PRTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Massachusetts Financial Services CO , based on Form 13F filings with the SEC.

News

Stay updated on Massachusetts Financial Services CO with notifications on news.

Account

Massachusetts Financial Services CO Prothena Corp Public LTD CO Transaction History